From Smart Fabrics to FDA’s TEMPO Pilot: Four Frontiers Reshaping Digital Health

Digital health is no longer a niche corner of medicine; it has become the arena where some of the most consequential questions about care, technology, and ethics are being decided. This week, JMIR Publications released four feature News and Perspectives articles that together offer a sweeping view of that arena, spanning the clinic, the laboratory, the regulator’s office, and the public forums where millions of people share their most personal experiences. Taken as a whole, the package reads less like a collection of isolated stories and more like a snapshot of a field in transition, one in which smartphones, sensors, artificial intelligence, and social platforms are simultaneously expanding what medicine can do and complicating how it should be governed.

The first of the four features turns to India, where a condition that most of the world still knows as polycystic ovary syndrome has been renamed polyendocrine metabolic ovarian syndrome, or PMOS, earlier this year. In the article, correspondent Bharath Thampi speaks with physicians and patients about the condition’s persisting stigma and the formidable barriers that stand between many Indian women and adequate care. The renaming itself signals a conceptual shift: rather than framing the syndrome narrowly around ovarian cysts, the new terminology reflects a broader understanding of it as a metabolic and endocrine disorder with wide-ranging consequences. That reframing matters clinically, but as Thampi’s reporting makes clear, terminology alone cannot close the treatment gap that separates urban specialists from rural patients.

Diagnosis and treatment of PMOS remain particularly inaccessible in rural regions of India, where specialist endocrinology and gynecology services are scarce and awareness of the condition is often limited. Yet the feature identifies reasons for cautious optimism rooted in the country’s rapid digital adoption. Reproductive health awareness has improved as smartphones and social media have spread, giving girls and women access to information that was previously out of reach. More strikingly, digital twin technology is beginning to be harnessed to develop individualized treatment plans for PMOS patients, creating computational models of individual physiology that can be used to simulate and refine therapeutic strategies before they are applied in the clinic. According to expert source Dr. Paramesh Shamanna, app-delivered treatment plans may one day be accessible and affordable to girls and women in rural regions as well, a prospect that would extend specialist-level personalization to populations that have historically been the last to benefit from medical innovation.

The second feature asks a deceptively simple question: is it time to ask more of our fabrics? In her article, correspondent Virginia Gewin surveys the nascent field of smart textiles, fabrics with technology literally woven in that can sense and track changes in health markers. The applications she describes stretch far beyond the fitness trackers that have made wearable sensing a consumer habit. Smart textiles are being developed for medical care, where they could monitor wound healing continuously without bulky equipment; for climate adaptability, where garments may respond to environmental conditions; and even for military operations, where physiological monitoring of personnel carries obvious strategic value. What distinguishes textiles from other wearables is their intimacy: a sensor woven into a bandage or a sleeve sits against the skin for hours or days, capturing physiological signals that occasional check-ins would miss entirely.

The most consequential development Gewin identifies, however, is a shift in ambition rather than in hardware. Researchers, she writes, are moving from simply sensing skin conditions to taking actions, such as delivering antibiotics or adjusting pressure in response to real-time swelling. That transition from passive monitoring to active intervention transforms the textile from a diagnostic instrument into a therapeutic one, and it raises a corresponding set of technical challenges. A fabric that dispenses medication must dose accurately, respond to biochemical cues reliably, and fail safely, all while surviving laundering, flexing, and the ordinary wear of daily life. The field is young, and the gap between laboratory demonstration and clinical deployment remains wide, but the direction of travel is unmistakable: the garment of the future may not merely record that something is wrong but begin fixing it before the wearer notices.

The third feature moves from the bedside to the regulator’s desk, where the United States Food and Drug Administration is quietly rethinking how it evaluates medical devices powered by artificial intelligence. Correspondent Tejas S Athni reports on the Technology-Enabled Meaningful Patient Outcomes pilot, known as TEMPO, a Digital Health Devices Pilot program that he describes as signaling a new regulatory approach for AI-enabled medical devices. The core innovation is procedural: the pilot provisionally enables certain manufacturers to launch digital health devices for clinical use before obtaining traditional FDA marketing authorization, while the agency evaluates their performance in real-world settings. In effect, the FDA is trading some of its customary premarket gatekeeping for the opportunity to observe how these products actually behave in hospitals, clinics, and patients’ homes.

The rationale for this experiment lies in the peculiar nature of AI-enabled devices themselves. Unlike a conventional stent or infusion pump, whose performance is fixed at the moment of manufacture, an AI-enabled device can perform dynamically in real-world settings, adapting its behavior as it encounters new data. Athni notes that this dynamism means traditional evaluation pathways may not be adequate for these products, since a device that changes after approval cannot be fully characterized by a premarket snapshot. In his framing, TEMPO represents an important experiment on how the FDA may regulate AI-enabled medical devices, providing regulators an opportunity to learn from technologies in real time. The stakes of that experiment extend well beyond the United States, because regulatory frameworks tend to propagate globally, and whatever the FDA learns from TEMPO will likely shape how health authorities elsewhere balance innovation against safety for a generation of adaptive medical software.

The fourth feature addresses a question that has grown urgent as artificial intelligence has made data extraction cheap and scalable: can information harvested from public forums be collected ethically? Correspondent Simon Spichak investigates the issue in an article on how to use, and how not to use, public forums in research. His reporting centers on a case that became a flashpoint for the research community in 2025, when the University of Zurich conducted an experiment on the subreddit /r/ChangeMyView without the knowledge of its users or moderators. Spichak speaks with a moderator of that community as well as internet research ethicist Dr. Amy Bruckman, using the episode to explore the widening gap between what research ethics rules technically permit and what online communities consider acceptable.

The structural problem, as Spichak documents, is that social media sites have been commonly mined for data by researchers even though most users are unaware, and a lack of explicit user consent is common among research that uses Reddit posts. Public forums occupy an ambiguous position: their content is technically public, yet the people who write it rarely imagine their words being analyzed, published, or fed into machine learning models. The rise of AI web scraping has intensified the tension, prompting Reddit and other companies to take matters into their own hands by restricting access to forums. That restriction, Spichak notes, will in turn require researchers to develop new strategies for ethical data collection, strategies that may include explicit consent mechanisms, community partnerships, and technical safeguards that respect both the letter of platform policy and the spirit of research ethics.

Viewed together, the four features trace a common thread through seemingly disparate domains. Whether the subject is a metabolic syndrome in rural India, a bandage that dispenses antibiotics, an adaptive diagnostic algorithm, or a subreddit whose users never consented to being studied, each story concerns a technology that outpaces the existing structures meant to govern it. JMIR Publications, a leading open access publisher of digital health research, launched its News and Perspectives section precisely to bring the rigor and integrity of academic publishing to scientific journalism, drawing on Scientific News Editor Kayleigh-Ann Clegg, PhD, and a network of specialist correspondents. The week’s package demonstrates why that mission matters: the questions raised by digital health are too consequential, and too fast-moving, to be left to any single discipline. Closing treatment gaps, weaving intelligence into fabric, regulating adaptive machines, and protecting the people whose data fuels it all are not separate problems but facets of one, and the answers will require clinicians, engineers, regulators, and communities to keep talking to each other.

Subject of Research: Digital health innovations including smart textiles, PMOS treatment in India, FDA regulation of AI-enabled medical devices, and online research ethics

Article Title: JMIR news: PMOS care, smart textiles, online research ethics, and the TEMPO pilot

Article References: JMIR news: PMOS care, smart textiles, online research ethics, and the TEMPO pilot. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: digital health, smart textiles, PMOS, polycystic ovary syndrome, FDA, TEMPO pilot, AI-enabled medical devices, research ethics, Reddit, data mining, digital twin, India